Skip to content

What the HHT?

A blog for the HHT community

This Landmark HHT Study Could Shift National Attention

We’re excited to share some truly important news for the HHT community. A major new study done in collaboration between Cure HHT, Massachusetts General Hospital, and Diagonal Therapeutics — just published in the American Journal of Hematology — delivers something we’ve never had before: hard data that proves HHT is a serious, high-impact disease that’s…

Read More

A Major Step Forward for HHT Treatment: Promising Preclinical Data from Diagonal Therapeutics

We’re excited to share two important updates from our partners at Diagonal Therapeutics. At this week’s European Hematology Association (EHA) Congress, Diagonal Therapeutics presented promising preclinical data demonstrating the potential of their antibody approach to address key challenges in HHT disease manifestations: Restoring ALK1-mediated cellular signaling Preventing and reversing arteriovenous malformations Preventing HHT-associated anemia And just recently…

Read More

Beyond: Looking at the Diverse Faces of HHT

Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that, despite being present from birth, often goes undiagnosed for many years. A common scenario involves a family member receiving a diagnosis, which then prompts others to seek testing. Even without genetic confirmation, a clinical diagnosis can be made based on characteristic symptoms. The variability in how…

Read More

Innovative Hematology Achieves Prestigious HHT Center of Excellence Certification

We are thrilled to share that Innovative Hematology, home to the Indiana Hemophilia and Thrombosis Center (IHTC), has officially earned the coveted designation as an HHT Center of Excellence. This marks another significant step forward in our fight to increase access to specialized care for our community. This prestigious certification places Innovative Hematology among an…

Read More
Scroll To Top